Vitamin K (PIVKA-II): Evidence-Based Ways to Improve Your Number

By Medically reviewed by Elena Vasquez, MD, FACOG
Published Updated Last reviewed

At a glance

  • Normal PIVKA-II / <2.0 ng/mL (some labs <40 mAU/mL; always use your lab's reference range)
  • High PIVKA-II means / vitamin K is functionally deficient, even if serum K1 looks normal
  • Bone connection / under-carboxylated osteocalcin rises alongside PIVKA-II, raising fracture risk
  • Menopause relevance / estrogen loss accelerates bone remodeling; low vitamin K compounds this
  • Pregnancy note / vitamin K supplementation in late pregnancy reduces neonatal hemorrhage risk
  • Top dietary sources / fermented natto, hard cheeses, leafy greens (K1), egg yolks (K2)
  • Key drug interaction / warfarin intentionally raises PIVKA-II; do not self-supplement without clinician guidance
  • Time to improvement / 4 to 8 weeks of consistent K2 supplementation can reduce PIVKA-II measurably

What PIVKA-II Actually Measures (and Why It Matters More Than Serum K1)

PIVKA-II is a protein your liver makes when it does not have enough vitamin K to complete the carboxylation step on prothrombin (clotting factor II). Think of it as the unfinished version of prothrombin: detectable in blood precisely because the vitamin K-dependent finishing process stalled. A high PIVKA-II level tells you the vitamin K pipeline is backed up, regardless of what a standard serum K1 test says.

Standard serum phylloquinone (K1) reflects only recent dietary intake, not what is actually reaching your bones and clotting cascade. PIVKA-II captures functional deficiency with greater sensitivity across the population, making it the preferred marker in research settings and increasingly in clinical practice.

How the Two Forms of Vitamin K Work

Vitamin K exists mainly as two forms relevant to your health:

  • K1 (phylloquinone): Found in leafy greens. Preferentially routed to the liver to support clotting factor synthesis.
  • K2 (menaquinones, MK-4 through MK-13): Found in fermented foods and animal products. Stays in circulation longer and reaches extrahepatic tissues including bone, arteries, and kidneys.

MK-7, the long-chain menaquinone in natto and supplements, has a half-life of approximately 72 hours, compared with roughly 1 to 2 hours for K1. That longer half-life means MK-7 is far more effective at carboxylating osteocalcin in bone tissue, and at bringing PIVKA-II down over time.

Why PIVKA-II Is the Functional Test

The carboxylation of prothrombin requires vitamin K as a co-factor. When vitamin K is insufficient, uncarboxylated prothrombin accumulates. That uncarboxylated form is exactly what PIVKA-II assays detect. A landmark 1997 study in the American Journal of Clinical Nutrition showed PIVKA-II elevated in 30 to 40% of otherwise healthy older adults who had serum K1 levels within normal limits, demonstrating that serum K1 alone misses a meaningful proportion of functionally deficient people.

What Is a Normal PIVKA-II Level?

Most clinical laboratories report a normal PIVKA-II as below 2.0 ng/mL using immunoassay methods, or equivalently below 40 mAU/mL on older arbitrary unit scales. Always interpret your result against the reference range printed on your own lab report, because assay calibration differs between manufacturers.

What a High PIVKA-II Means

A PIVKA-II above the upper reference limit means your body is not carboxylating vitamin K-dependent proteins adequately. Clinically, this can reflect:

  • Dietary deficiency: Very low intake of both K1 and K2, common in restrictive or low-fat diets (fat is required for absorption).
  • Fat malabsorption: Conditions like celiac disease, Crohn's disease, short bowel syndrome, or pancreatic insufficiency reduce K absorption significantly.
  • Medication effect: Warfarin, broad-spectrum antibiotics that disrupt gut flora, and certain anticonvulsants all drive PIVKA-II up. Warfarin elevates PIVKA-II intentionally as its mechanism of action; supplementing without medical supervision is dangerous on this drug.
  • Liver disease: The liver performs carboxylation. Hepatic dysfunction raises PIVKA-II independent of dietary intake, and PIVKA-II is also used as a hepatocellular carcinoma biomarker in oncology contexts at much higher thresholds.

What a Low PIVKA-II Means

A PIVKA-II below the lower reference limit is not a recognized clinical problem. There is no known harm from having very efficient vitamin K carboxylation. If your result is flagged as "low," this is almost certainly a lab formatting artifact rather than a pathological finding.

Why This Matters Specifically for Women

Women carry a disproportionate share of vitamin K-related health burdens. Osteoporosis affects approximately 20% of women over 50 in the United States, compared with 5% of men in the same age group. Vitamin K is not a calcium substitute, but it is a required co-factor for activating osteocalcin, the bone matrix protein that binds calcium into bone crystal.

Reproductive Years and PCOS

Women with polycystic ovary syndrome (PCOS) show higher rates of insulin resistance, and a 2019 randomized controlled trial published in Clinical Nutrition found that 90 mcg/day of MK-7 for 12 weeks significantly improved insulin sensitivity and reduced markers of inflammation in women with PCOS compared with placebo. PIVKA-II was not the primary endpoint, but the trial confirmed systemic vitamin K insufficiency as a modifiable variable in this population.

Fat-soluble vitamins including K are also absorbed less efficiently when gut transit is altered by metformin, a first-line PCOS medication. If you take metformin, ask your clinician whether periodic PIVKA-II monitoring makes sense for you.

Perimenopause and Menopause

Estrogen suppresses bone resorption. When estrogen falls during perimenopause, bone turnover accelerates sharply, and the demand for carboxylated osteocalcin rises. A 3-year randomized trial (the MaasTricht Osteocalcin MK-7 trial) published in Osteoporosis International in 2013 randomized 244 healthy postmenopausal women to 180 mcg/day MK-7 or placebo. The MK-7 group had significantly lower PIVKA-II, significantly higher carboxylated osteocalcin, and significantly attenuated decline in vertebral bone mineral density over three years compared with placebo.

The Menopause Society (formerly NAMS) does not yet include vitamin K2 in its core menopause management guidelines, but the Society's position statement on nonhormonal management of menopause acknowledges the importance of adequate micronutrient status for bone protection. Given the Maastricht trial data, optimizing PIVKA-II is a reasonable evidence-based target in postmenopausal women.

Pregnancy and Lactation

This section addresses pregnancy and lactation safety directly.

Vitamin K status during pregnancy is critical for fetal liver development and for preventing neonatal hemorrhagic disease. The fetus does not efficiently transport vitamin K across the placenta, making newborns transiently deficient at birth regardless of maternal intake. This is why all newborns receive an intramuscular vitamin K injection at delivery per ACOG and AAP joint guidance.

Supplementing during pregnancy: Dietary vitamin K from food is considered safe at any level during pregnancy. Supplemental K1 at doses used clinically (up to 1 mg/day) is not classified as teratogenic and is categorized as compatible with pregnancy by standard reference sources. High-dose K3 (menadione), a synthetic form, should be avoided in pregnancy due to hemolytic risk in the newborn; K1 and K2 do not share this risk.

Lactation: Vitamin K1 transfers into breast milk in small amounts. Breast milk is naturally low in vitamin K, which is why neonatal vitamin K injection at birth is essential even in breastfed infants. Maternal supplementation with K1 modestly increases milk K1 content but does not eliminate the need for neonatal prophylaxis. Supplementing with K2 MK-7 during lactation is not contraindicated, though direct human lactation data remain limited.

Warfarin in pregnancy: Warfarin is teratogenic (associated with warfarin embryopathy in the first trimester and fetal intracranial bleeding later in pregnancy). Women of reproductive age on warfarin require reliable contraception. This is stated explicitly in FDA prescribing information for warfarin. If you take warfarin and are planning pregnancy, work with your hematologist or cardiologist immediately to discuss bridging to low-molecular-weight heparin.

Evidence-Based Ways to Lower Your PIVKA-II

Lowering PIVKA-II means increasing the amount of functional vitamin K reaching your liver and extrahepatic tissues. The strategies with the most direct human evidence are below.

1. Increase Dietary Vitamin K2 (Especially MK-7)

Natto (fermented soybeans) is the single richest food source of MK-7, providing approximately 900 to 1,000 mcg per 100 g serving. One small serving per week has been associated with measurably lower PIVKA-II in observational studies of Japanese populations. Other meaningful K2 sources include:

| Food | Form | Approximate K2 per 100 g | |---|---|---| | Natto | MK-7 | 900 to 1,000 mcg | | Gouda cheese | MK-8, MK-9 | 75 mcg | | Brie | MK-8, MK-9 | 56 mcg | | Egg yolk | MK-4 | 32 mcg | | Chicken liver | MK-4 | 14 mcg | | Butter (grass-fed) | MK-4 | 15 mcg |

Increasing K1 intake (leafy greens) also helps hepatic carboxylation and can reduce PIVKA-II, though the effect on extrahepatic tissues like bone is less pronounced than with K2.

2. Supplement with MK-7

The most studied supplemental dose for PIVKA-II reduction is 90 to 360 mcg/day of MK-7. The 180 mcg/day dose used in the Maastricht trial brought PIVKA-II to undetectable levels in most participants within 8 weeks. Take MK-7 with your largest fat-containing meal, as vitamin K is fat-soluble and absorption drops significantly without dietary fat.

MK-4 supplements at pharmacological doses (1.5 to 45 mg/day) have been used in Japanese osteoporosis trials with positive bone outcomes, but these doses are prescription-grade in Japan and are not standard in the United States. For most women in the United States, 100 to 200 mcg/day of MK-7 is the practical starting point.

Do not supplement if you take warfarin without explicit guidance from your prescribing clinician. Even modest increases in vitamin K intake shift your INR.

3. Optimize Fat Absorption

Vitamin K requires bile acids and dietary fat for micellar absorption in the small intestine. If you have had gallbladder removal, follow a very-low-fat diet, or take orlistat or cholestyramine, your vitamin K absorption may be structurally impaired regardless of intake. Orlistat reduces fat-soluble vitamin absorption by up to 30% and is often prescribed to women for weight management. If you take orlistat, a multivitamin containing K taken at least 2 hours apart from the drug dose is a reasonable precaution.

4. Address Gut Microbiome Health

Gut bacteria, particularly in the colon, synthesize menaquinones that contribute to the body's vitamin K pool. Repeated or prolonged antibiotic courses disrupt this synthesis. A 2019 review in Nutrients confirmed that broad-spectrum antibiotics reliably raise PIVKA-II within 5 to 7 days of administration. Fermented food intake and targeted probiotic support after antibiotic courses may help restore baseline menaquinone production, though direct PIVKA-II trial data on probiotics remain preliminary.

5. Review Your Medications

Several drug classes raise PIVKA-II by interfering with vitamin K cycling:

  • Warfarin and other vitamin K antagonists: Mechanism-based; do not counteract without supervision.
  • Cholestyramine and colestipol: Bile acid sequestrants reduce K absorption.
  • Cephalosporin antibiotics with the NMTT side chain (e.g., cefoperazone, cefamandole): Directly inhibit vitamin K epoxide reductase, the enzyme that recycles vitamin K.
  • Anticonvulsants (phenytoin, phenobarbital, carbamazepine): Induce CYP enzymes that accelerate vitamin K catabolism. Women on long-term anticonvulsants have significantly higher fracture rates, partly attributable to compromised vitamin K-dependent bone protein activity.

If you take any of these drugs chronically, periodic PIVKA-II monitoring gives you and your clinician an objective measure of functional vitamin K status.

Who This Is Right For (and Who Should Be Cautious)

Good candidates for optimizing PIVKA-II

  • Perimenopausal and postmenopausal women with low bone mineral density or high fracture risk, especially if calcium and vitamin D are already optimized.
  • Women with PCOS managing insulin resistance with or without metformin.
  • Women on long-term antibiotics or anticonvulsants who have never had vitamin K status assessed.
  • Women following low-fat or highly restrictive dietary patterns (vegan diets tend to be high in K1 but low in K2; PIVKA-II testing can clarify functional status).
  • Women with fat malabsorption from any cause.
  • Postpartum women who are breastfeeding and want to maximize milk micronutrient quality (discuss with your midwife or OB).

Women who should not self-supplement without clinician guidance

  • Anyone on warfarin or another vitamin K antagonist. Full stop.
  • Women with a history of hypercoagulable states or clotting disorders where anticoagulation dosing is tightly managed.
  • Women with liver disease, where elevated PIVKA-II may reflect hepatic dysfunction rather than dietary deficiency, and where clinical interpretation must come first.

How to Track Your Progress

After starting dietary changes or MK-7 supplementation, allow 6 to 8 weeks before re-testing PIVKA-II. This matches the half-life kinetics of osteocalcin carboxylation turnover. In the Maastricht trial, PIVKA-II reached its nadir at approximately 8 weeks in most participants on 180 mcg/day MK-7.

A useful paired test is the carboxylated-to-undercarboxylated osteocalcin ratio (cOC:ucOC). When PIVKA-II falls, carboxylated osteocalcin typically rises. Tracking both gives you a fuller picture of whether your vitamin K is actually reaching bone tissue, not just the liver.

A practical monitoring schedule for a postmenopausal woman starting MK-7 supplementation:

  1. Baseline: PIVKA-II, carboxylated osteocalcin, 25-OH vitamin D, calcium.
  2. Week 8: Repeat PIVKA-II and carboxylated osteocalcin.
  3. If PIVKA-II normalized: Repeat annually or with any medication change.
  4. If PIVKA-II still elevated at 8 weeks: Assess for fat malabsorption (fecal elastase, celiac panel) and review medications before increasing dose further.

The Evidence Gap: What We Still Do Not Know

Women have been under-represented in vitamin K intervention trials overall. Most of the data on PIVKA-II and bone outcomes come from postmenopausal Japanese women, who consume significantly more dietary K2 from natto than Western populations. Evidence-based ways to improve this number in younger reproductive-age women, in women with PCOS, or in women across the perimenopause transition specifically are areas where large prospective trials are still missing. The Maastricht data are compelling but come from a single European cohort.

Extrapolating the Maastricht dose (180 mcg/day MK-7) to women under 50 or to women with PCOS is reasonable based on mechanism, but it is extrapolation. Your clinician should weigh this when making individual recommendations.

The WomanRx Life-Stage Vitamin K Framework:

| Life Stage | Primary K Concern | Preferred Marker | Suggested Action | |---|---|---|---| | Reproductive years (18 to 44) | Absorption, PCOS insulin resistance | PIVKA-II if symptomatic | Diet-first; MK-7 100 mcg/day if deficient | | TTC / Pregnancy | Fetal coagulation, neonatal hemorrhage | Serum K1 + PIVKA-II | Dietary K only unless clinician directs otherwise; ensure neonatal K shot | | Postpartum / Lactation | Milk K content, maternal bone | PIVKA-II at 6-week visit | MK-7 100 to 200 mcg/day; confirm neonatal injection given | | Perimenopause | Bone mineral density preservation | PIVKA-II + carboxylated osteocalcin | MK-7 180 mcg/day with calcium and D3 | | Postmenopause | Fracture prevention, arterial calcification | PIVKA-II + cOC:ucOC ratio | MK-7 180 mcg/day; warfarin users consult prescriber |

A Note on Vitamin K and Arterial Calcification

Matrix Gla Protein (MGP), another vitamin K-dependent protein, inhibits calcium deposition in arterial walls. Undercarboxylated MGP is associated with arterial stiffness and vascular calcification. A 2009 three-year trial in healthy postmenopausal women found that 180 mcg/day MK-7 significantly increased activated MGP and slowed carotid intima-media thickness progression compared with placebo. Cardiovascular disease is the leading cause of death in women over 65, making this a clinically meaningful observation, though not yet incorporated into cardiovascular prevention guidelines.

Frequently asked questions

›What is a normal Vitamin K (PIVKA-II) level?
Most laboratories set the upper reference limit at 2.0 ng/mL or 40 mAU/mL, though calibration varies between assay platforms. Always use the reference range on your own lab report. A result below this threshold indicates adequate functional vitamin K status for hepatic carboxylation. PIVKA-II does not have a clinically meaningful lower limit; a very low number simply means vitamin K carboxylation is working well.
›What does a high Vitamin K (PIVKA-II) mean?
A PIVKA-II above the upper reference limit means your liver is producing uncarboxylated prothrombin because vitamin K is functionally insufficient at the enzyme level. The most common causes are low dietary K1 and K2 intake, fat malabsorption (including from low-fat diets), warfarin use, long-term antibiotic courses, or liver disease. In the context of liver disease, very high PIVKA-II (hundreds to thousands of mAU/mL) is also used as a hepatocellular carcinoma screening marker at much higher thresholds than nutritional deficiency.
›What does a low Vitamin K (PIVKA-II) mean?
A result below the lower reference limit is not a recognized clinical problem. PIVKA-II has no established 'too low' threshold from a health standpoint. If your report flags a low value, confirm with your clinician that the result is not a lab formatting artifact.
›How do I lower my PIVKA-II naturally?
Increase dietary K2 through natto, hard cheeses like Gouda and Edam, egg yolks, and fermented foods. Supplement with 100 to 180 mcg per day of MK-7 taken with a fat-containing meal. Allow 6 to 8 weeks and retest. Address any underlying fat malabsorption and review medications that interfere with vitamin K cycling.
›How quickly does PIVKA-II respond to supplementation?
In the Maastricht MK-7 trial using 180 mcg per day, PIVKA-II reached its nadir in most women within 8 weeks of consistent supplementation. Carboxylated osteocalcin, the bone marker, took slightly longer to show its maximum response. Dietary changes alone may take longer, given that natto consumption habits are harder to sustain at therapeutic levels in non-Japanese populations.
›Can I take vitamin K2 if I am on warfarin?
No, not without direct guidance from your prescribing clinician. Warfarin works by blocking vitamin K recycling, and adding K2 supplements will shift your INR in an unpredictable direction. This is a safety-critical interaction. Do not self-supplement with any form of vitamin K while on warfarin or other vitamin K antagonists.
›Does vitamin K2 help with osteoporosis in menopause?
The evidence is most direct for postmenopausal women. The 2013 Maastricht randomized controlled trial showed that 180 mcg per day of MK-7 significantly attenuated vertebral bone mineral density loss over three years compared with placebo in 244 postmenopausal women. It also significantly reduced PIVKA-II and increased carboxylated osteocalcin. Vitamin K2 is not a replacement for calcium, vitamin D, or osteoporosis medications, but it addresses a different and complementary mechanism in bone matrix protein activation.
›Is vitamin K2 safe during pregnancy?
Dietary vitamin K at any intake level and supplemental K1 or K2 at doses used clinically are not classified as teratogenic. K3 (menadione, a synthetic form) should be avoided in pregnancy due to hemolytic risk. The most critical vitamin K intervention in pregnancy is the intramuscular K1 injection given to newborns at birth to prevent hemorrhagic disease of the newborn, which is standard of care per ACOG and AAP guidance. Always discuss any supplementation during pregnancy with your OB or midwife.
›Why is serum vitamin K1 not enough to assess my status?
Serum phylloquinone (K1) reflects only recent dietary intake and fluctuates widely within hours of a meal. It does not tell you whether vitamin K is actually reaching your bones and clotting cascade at a functional level. PIVKA-II captures whether the vitamin K-dependent carboxylation process is working, making it a more meaningful clinical measurement for assessing tissue-level sufficiency.
›Which foods are highest in vitamin K2?
Natto (fermented soybeans) tops the list at roughly 900 to 1,000 mcg of MK-7 per 100 g. Hard cheeses like Gouda and Edam provide 50 to 75 mcg of MK-8 and MK-9 per 100 g. Egg yolks, chicken liver, and grass-fed butter provide MK-4, though at lower concentrations. Most leafy greens are rich in K1, not K2, and while helpful for hepatic clotting factor function, K1 is less effective at raising carboxylated osteocalcin in bone.
›Should women with PCOS check their PIVKA-II?
PIVKA-II testing is not a standard part of PCOS workup in any current guideline, but there is a rationale for checking it in women with PCOS who have significant insulin resistance or who are on metformin long-term. The 2019 Clinical Nutrition trial showed MK-7 improved insulin sensitivity markers in women with PCOS, suggesting that functional vitamin K insufficiency may be worth assessing and treating in this population. Discuss with your clinician whether adding PIVKA-II to your metabolic panel makes sense.

References

  1. Suttie JW. The importance of menaquinones in human nutrition. Annu Rev Nutr. 2012;32:31-48.
  2. Schurgers LJ, Teunissen KJ, Hamulyak K, et al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007;109(8):3279-83.
  3. Booth SL, Sokoll LJ, O'Brien ME, et al. Assessment of dietary phylloquinone intake and vitamin K status in postmenopausal women. Am J Clin Nutr. 1997;66(4):960-6.
  4. Oldenburg J, Bevans CG, Muller CR, Watzka M. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal. 2006;8(3-4):347-53.
  5. Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013;24(9):2499-507.
  6. Ferland G. Vitamin K and the nervous system: an overview of its actions. Adv Nutr. 2012;3(2):204-12.
  7. Razavi M, Jamilian M, Kashan ZF, et al. Vitamin K supplementation and the effects on glycemic indices, lipid profile, and inflammatory markers in women with polycystic ovary syndrome. Clin Nutr. 2019;38(5):2132-8.
  8. Pericleous M, Mandair D, Caplin ME. Diet and supplements and their impact on colorectal cancer. J Gastrointest Oncol. 2013;4(4):409-23.
  9. Greer FR, Marshall SP, Foley AL, Suttie JW. Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements. Pediatrics. 1997;99(1):88-92.
  10. Food and Drug Administration. Warfarin sodium prescribing information. accessdata.fda.gov. 2011.
  11. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000;57(13):1221-7.
  12. Fusaro M, Gallieni M, Rizzo MA, et al. Vitamin K plasma levels determination in human health. Clin Chem Lab Med. 2017;55(6):789-799.
  13. Knapen MH, Braam LA, Drummen NE, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomised clinical trial. Thromb Haemost. 2015;113(5):1135-44.
  14. Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 2012;11:93.
  15. American College of Obstetricians and Gynecologists. Vitamin K prophylaxis for the prevention of vitamin K deficiency bleeding in neonates. Committee Opinion No. 801. [acog.org. 2023.](https
From$99/mo·
Take the quiz →